PA Fasching
- Cancer Research top 5%
- Breast Cancer Treatment Studies 30
- Pharmacology top 5%
- Oncology top 10%
- Cancer Treatment and Pharmacology 30
- HER2/EGFR in Cancer Research 20
- Cancer Cells and Metastasis 7
- Reproductive Medicine top 10%
- Endometriosis Research and Treatment 6
- Genetics top 10%
- BRCA gene mutations in cancer 7
- Estrogen and related hormone effects 6
-
- Advanced Breast Cancer Therapies 43
- Co-authors
- Michael P. LuxTanja FehmWerner SchrothHiltrud BrauchStefan WinterMichel EichelbaumGeorg HeinkeleWolfgang Simon
- Cited by
- Cancer ResearchPharmacologyOncology
- Journals
- Journal of Clinical Oncology (2 papers)Cancer Research (28 papers)Clinical Cancer Research (1 paper)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
PA Fasching
86 papers receiving 940 citations
Peers
Comparison fields: 5 of 89
- Cancer Research 328
- Pharmacology 162
- Oncology 440
- Reproductive Medicine 84
- Genetics 229
Countries citing papers authored by PA Fasching
This map shows the geographic impact of PA Fasching's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PA Fasching with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PA Fasching more than expected).
Fields of papers citing papers by PA Fasching
This network shows the impact of papers produced by PA Fasching. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PA Fasching. The network helps show where PA Fasching may publish in the future.
Co-authorship network
The 25 scholars most cited alongside PA Fasching, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 4 | |
| 3 | 2023 | 33 | |
| 4 | 2023 | 1 | |
| 5 | 2020 | 3 | |
| 6 | 2019 | 22 | |
| 7 | 2019 | 1 | |
| 8 | 2017 | 1 | |
| 9 | Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3 | 2016 | 3 |
| 10 | Integrative Medicine in Gynecologic Oncology - Possibilities and Limits Part 1 | 2013 | 2 |
| 11 | 2013 | 24 | |
| 12 | 2012 | 18 | |
| 13 | 2012 | 5 | |
| 14 | 2011 | 26 | |
| 15 | 2011 | 48 | |
| 16 | 2011 | 1 | |
| 17 | 2010 | 34 | |
| 18 | 2008 | 81 | |
| 19 | 2008 | 31 | |
| 20 | 2007 | 33 |
About PA Fasching
PA Fasching is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 92 papers that have together received 969 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (43 papers), Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (20 papers), BRCA gene mutations in cancer (7 papers), Cancer Cells and Metastasis (7 papers), Endometriosis Research and Treatment (6 papers) and Estrogen and related hormone effects (6 papers). The work is most often cited by research in Cancer Research (328 citations), Pharmacology (162 citations) and Oncology (440 citations). PA Fasching has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Michael P. Lux, Tanja Fehm, Werner Schroth, Hiltrud Brauch, Stefan Winter, Michel Eichelbaum, Georg Heinkele, Wolfgang Simon, Matthias Schwab and M.W. Beckmann. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.